胸部放疗临床试验入组率及未入组原因:大型前瞻性多年分析
该研究前瞻性追踪2016至2019年在本机构接受胸部放疗会诊患者的试验筛查与入组情况,共分析2372例患者,涉及17项放疗试验。结果显示仅11.9%(281例)最终入组,40.0%被判定不合格或不愿继续筛查,58%的可潜在合格患者因纳入排除标准未入组。
要点
- 2372例筛查患者中仅281例(11.9%)最终入组临床试验。
- 40.0%患者被判定不合格或不愿继续筛查,不合格原因以分期(44%)为主。
- 可潜在合格患者中58%因纳入排除标准未入组,14%因患者拒绝。
核心结论
- 筛查胸部放疗临床试验的患者中仅约12%最终入组,超过三分之二无可用试验或被判定不合格。
- 可潜在合格患者中19%因患者或医生拒绝而未入组。
- 未来试验或可从更包容的入组标准与转诊医生的多学科参与中获益。
研究设计与样本
- 前瞻性数据库追踪2016至2019年在本机构接受胸部放疗会诊并接受筛查的患者。
- 共分析2372例患者,涉及17项放疗试验,比较入组率、患者与疾病特征、社会经济因素及未入组原因。
主要发现
- 2372例中281例(11.9%)入组。
- 40.0%(949例)被判定为任何试验均不合格(NE)或不愿进一步筛查。
- 不合格原因包括分期(44%)、组织学(13%)、无放疗指征(12%)、患者决定(7%)、参加竞争性内科或外科肿瘤试验(5%)。
- 其余60.0%(1423例)为潜在合格(PE),多为非小细胞肺癌(71%)或食管癌(16%);PE组IV期患者(29%)显著少于NE组(49%)(P < .0001)。
- 未入组原因包括纳入排除标准(58%)、患者拒绝(14%)、医生决定(5%)。
关键数值与推荐
- PE组白人比例高于NE组(82.5% vs 75.8%;P < .001)。
- 入组与未入组PE患者间,白人种族(87.9% vs 81.2%;P = .008)、偏好英语(96.4% vs 92.9%;P = .032)、非西班牙裔/拉丁裔(94.0% vs 90.1%;P = .042)存在显著差异。
临床怎么用
- 筛查胸部放疗临床试验时应关注分期与组织学等常见不合格原因,优化试验设计。
- 需重视患者与医生拒绝导致的未入组,加强转诊医生参与和患者沟通。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Clinical trials are considered the gold standard in evidence-based medicine, yet few patients with cancer ultimately enroll. Here we examine patients screened for thoracic radiation oncology clinical trials to better understand enrollment trends. METHODS AND MATERIALS: A prospective database tracking screening and enrollment for patients referred for thoracic radiation oncology consultation at our institution from 2016 to 2019 was evaluated. Proportional enrollment rates, patient and disease characteristics, self-reported socioeconomic factors, and reasons for ineligibility or nonenrollment across 17 radiation therapy trials were compared. RESULTS: Enrollment data on 2372 patients were available for analysis. Of these patients, 40.0% (949) were deemed "not eligible" (NE) for any trial or were unwilling to be further screened. Reasons for ineligibility included stage (44%), histology (13%), radiation therapy not indicated (12%), patient decision (7%), and enrollment in a competing medical or surgical oncology trial (5%). The remaining 60.0% (1423) were "potentially eligible" (PE) for one or more trials. Most had non-small cell lung cancer (71%) or esophageal cancer (16%), and there were significantly fewer stage IV PE (29%) versus NE (49%) patients (P < .0001). Of 2372 patients, 281 (11.9%) enrolled. Notable reasons for nonenrollment were inclusion and exclusion criteria (58%), patients declining enrollment (14%), and physician decision (5%). The proportion of white patients was higher in the PE versus NE group (82.5% vs 75.8%; P < .001). Additionally, white race (87.9% vs 81.2%; P = .008), English language preference (96.4% vs 92.9%; P = .032), and non-Hispanic/Latino ethnicity (94.0% vs 90.1%; P = .042) were significantly different in enrolled versus nonenrolled PE patients. CONCLUSIONS: Only 12% of patients screened for radiation therapy trials ultimately enrolled, and more than two-thirds had no trial available or were found ineligible. In addition, 19% of potential eligible patients did not enroll because the patient or physician declined. Future trials may benefit from pragmatic designs with more inclusive enrollment criteria and multidisciplinary engagement of referring providers.
引用
- Mesko S, Ning MS, Lakomy D, et al. Thoracic Radiation Oncology Clinical Trial Accrual and Reasons for Nonenrollment: Results of a Large, Prospective, Multiyear Analysis. Int J Radiat Oncol Biol Phys. 2020. PMID: 32360653. doi:10.1016/j.ijrobp.2020.04.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。